Patents by Inventor Xue-hai Liang
Xue-hai Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002851Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: ApplicationFiled: January 25, 2023Publication date: January 4, 2024Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-Hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Patent number: 11629348Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: GrantFiled: February 15, 2022Date of Patent: April 18, 2023Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Publication number: 20230068063Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: ApplicationFiled: March 17, 2022Publication date: March 2, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Patent number: 11492617Abstract: In certain embodiments, the present disclosure provides methods comprising contacting a cell with a compound comprising a modified oligonucleotide complementary to a nucleic acid transcript. In certain such embodiments, the modified oligonucleotide does not interact or interacts poorly with a mRNP complex or granule. In certain such embodiments the modifications and/or motifs of the modified oligonucleotide do not promote interaction with a mRNP complex or granule. In certain embodiments, the present disclosure provides methods comprising contacting a cell with a compound comprising a modified oligonucleotide thereby reducing the size or amount of protein aggregation in the cell. In certain such embodiments, the protein aggregate is a mRNP granule. In certain such embodiments, the modifications and/or motifs of the modified oligonucleotide promote interaction with a protein aggregate, such as a mRNP granule, that results in disruption of the protein aggregate.Type: GrantFiled: August 7, 2018Date of Patent: November 8, 2022Assignee: Ionis Pharmaceuticals, IncInventors: C. Frank Bennett, Xue-hai Liang, Wen Shen
-
Publication number: 20220186222Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.Type: ApplicationFiled: February 15, 2022Publication date: June 16, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
-
Patent number: 11332733Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: GrantFiled: February 12, 2019Date of Patent: May 17, 2022Assignee: lonis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20210380976Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having one or more chirally enriched phosphorothioate intemucleoside linkages. In certain embodiments, the modified oligonucleotide decreases expression of target mRNA.Type: ApplicationFiled: October 4, 2019Publication date: December 9, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20210355493Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide that induces no-go decay of a target mRNA. In certain embodiments, the modified oligonucleotide is complementary to a region within the 3? half of the coding region of the target mRNA.Type: ApplicationFiled: October 4, 2019Publication date: November 18, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Xue-hai Liang, Joshua Nichols, Stanley T. Crooke
-
Patent number: 11149264Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: GrantFiled: February 10, 2021Date of Patent: October 19, 2021Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20210269472Abstract: In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell. In certain embodiments, the compounds comprise a translation suppression element inhibitor. In certain embodiments, the translation suppression element inhibitor is a uORF inhibitor. In certain embodiments, the uORF inhibitor is an antisense compound.Type: ApplicationFiled: September 15, 2020Publication date: September 2, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Stanley T. Crooke, Xue-hai Liang, Wen Shen
-
Publication number: 20210261945Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: ApplicationFiled: February 10, 2021Publication date: August 26, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20210171945Abstract: Disclosed herein are methods for increasing antisense activity by modulating translation. In certain embodiments, a compound comprising an antisense oligonucleotide is co-administered with an inhibitor of translation.Type: ApplicationFiled: November 16, 2018Publication date: June 10, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Xue-hai Liang, Stanley T. Crooke
-
Publication number: 20210017513Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.Type: ApplicationFiled: February 12, 2019Publication date: January 21, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
-
Publication number: 20200407717Abstract: Disclosed herein are methods for increasing antisense activity by modulating EGFR. In certain embodiments, a compound comprising an antisense oligonucleotide is co-administered with an EGFR modulator.Type: ApplicationFiled: February 13, 2019Publication date: December 31, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Shiyu Wang, Alexey Revenko, Xue-hai Liang, Stanley T. Crooke
-
Patent number: 10822369Abstract: In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell. In certain embodiments, the compounds comprise a translation suppression element inhibitor. In certain embodiments, the translation suppression element inhibitor is a uORF inhibitor. In certain embodiments, the uORF inhibitor is an antisense compound.Type: GrantFiled: November 16, 2015Date of Patent: November 3, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Stanley T. Crooke, Xue-hai Liang, Wen Shen
-
Publication number: 20200239888Abstract: In certain embodiments, the present disclosure provides methods comprising contacting a cell with a compound comprising a modified oligonucleotide complementary to a nucleic acid transcript. In certain such embodiments, the modified oligonucleotide does not interact or interacts poorly with a mRNP complex or granule. In certain such embodiments the modifications and/or motifs of the modified oligonucleotide do not promote interaction with a mRNP complex or granule. In certain embodiments, the present disclosure provides methods comprising contacting a cell with a compound comprising a modified oligonucleotide thereby reducing the size or amount of protein aggregation in the cell. In certain such embodiments, the protein aggregate is a mRNP granule. In certain such embodiments, the modifications and/or motifs of the modified oligonucleotide promote interaction with a protein aggregate, such as a mRNP granule, that results in disruption of the protein aggregate.Type: ApplicationFiled: August 7, 2018Publication date: July 30, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Xue-hai Liang, Wen Shen
-
Patent number: 10370659Abstract: In certain embodiments, the present disclosure provides compounds and methods for increasing the antisense activity of an antisense compound in a cell. In certain embodiments, the present disclosure provides methods for identifying antisense compounds having high activity. In certain embodiments, the present disclosure provides methods for identifying antisense compounds that bind to enhancer or repressor proteins.Type: GrantFiled: February 23, 2016Date of Patent: August 6, 2019Assignee: Ionis Pharmaceuticals, Inc.Inventors: Xue-hai Liang, Wen Shen, Stanley T. Crooke
-
Publication number: 20180201930Abstract: The present invention provides compounds and methods for modulating target nucleic acids found in organelles or sub-organelles of cells. The invention includes, but is not limited to compounds and methods that modulate target nucleic acids in a sub-nuclear organelle, such as the nucleolus and/or a cajal body. In certain embodiments, the cell is in an animal.Type: ApplicationFiled: November 10, 2017Publication date: July 19, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Xue-hai Liang, Stanley T. Crooke
-
Publication number: 20180148718Abstract: In certain embodiments, the present disclosure provides compounds and methods for increasing the antisense activity of an antisense compound in a cell. In certain embodiments, the present disclosure provides methods for identifying antisense compounds having high activity. In certain embodiments, the present disclosure provides methods for identifying antisense compounds that bind to enhancer or repressor proteins.Type: ApplicationFiled: February 23, 2016Publication date: May 31, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Xue-hai Liang, Wen Shen, Stanley T. Crooke
-
Publication number: 20180087107Abstract: The present invention provides compounds and methods for competitive modulation of microRNAs. Such copounds and methods have profound effects on cells.Type: ApplicationFiled: June 27, 2017Publication date: March 29, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Xue-hai Liang, Stanley T. Crooke